{{Drugbox
| verifiedrevid = 456692175
| IUPAC_name = 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol
| image = Amodiaquine.svg
| width = 250

<!--Clinical data-->
| tradename =  Amdaquine, Amobin, others<ref>{{cite web|title=Amodiaquine|url=https://www.drugs.com/international/amodiaquine.html|website=drugs.com|accessdate=27 November 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161127154249/https://www.drugs.com/international/amodiaquine.html|archivedate=27 November 2016|df=}}</ref>
| Drugs.com = {{drugs.com|international|amodiaquine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->

<!--Pharmacokinetic data-->
| elimination_half-life =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 86-42-0
| ATC_prefix = P01
| ATC_suffix = BA06
| PubChem = 2165
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00613
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2080
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 220236ED28
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02922
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2674
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 682

<!--Chemical data-->
| C=20 | H=22 | Cl=1 | N=3 | O=1 
| molecular_weight = 355.861 g/mol
| smiles = Clc1cc2nccc(c2cc1)Nc3cc(c(O)cc3)CN(CC)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OVCDSSHSILBFBN-UHFFFAOYSA-N
}}
<!-- Definition and medical uses -->
'''Amodiaquine''' ('''ADQ''') is a medication used to treat [[antimalarial|malaria]], including ''Plasmodium falciparum'' malaria when uncomplicated.<ref name=Na2012>{{cite journal|last1=Nair|first1=A|last2=Abrahamsson|first2=B|last3=Barends|first3=DM|last4=Groot|first4=DW|last5=Kopp|first5=S|last6=Polli|first6=JE|last7=Shah|first7=VP|last8=Dressman|first8=JB|title=Biowaiver monographs for immediate release solid oral dosage forms: amodiaquine hydrochloride.|journal=Journal of pharmaceutical sciences|date=December 2012|volume=101|issue=12|pages=4390–401|pmid=22949374}}</ref><ref name=Co2003>{{cite journal|last1=Olliaro|first1=P|last2=Mussano|first2=P|title=Amodiaquine for treating malaria.|journal=The Cochrane database of systematic reviews|date=2003|issue=2|pages=CD000016|pmid=12804382}}</ref> It is recommended to be given with [[artesunate]] to reduce the risk of resistance.<ref name=Na2012/> Due to the risk of rare but serious side effects, it is not generally recommended to prevent malaria.<ref name=Na2012/>

<!-- Side effects and mechanism -->
The side effects of amodiaquine are generally minor to moderate and are similar to those of [[chloroquine]].<ref name=Co2003/> Rarely [[liver problems]] or [[agranulocytosis|low blood cell levels]] may occur.<ref name=Na2012/> When taken in excess headaches, trouble seeing, [[seizures]], and [[cardiac arrest]] may occur.<ref name=Na2012/> While not extensively studied as of 2007, it appeared to be safe in pregnancy.<ref>{{cite journal|last1=Tagbor|first1=HK|last2=Chandramohan|first2=D|last3=Greenwood|first3=B|title=The safety of amodiaquine use in pregnant women.|journal=Expert opinion on drug safety|date=November 2007|volume=6|issue=6|pages=631–5|pmid=17967151}}</ref> Amodiaquine is a [[4-aminoquinoline]] compound related to chloroquine.<ref name=Na2012/>

<!-- History and culture -->
Amodiaquine was first made in 1948.<ref>{{cite book|title=Profiles of Drug Substances, Excipients and Related Methodology|date=1992|publisher=Academic Press|isbn=9780080861166|page=45|url=https://books.google.com/books?id=3mP9TYffnewC&pg=PA44|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170908213921/https://books.google.com/books?id=3mP9TYffnewC&pg=PA44|archivedate=2017-09-08|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> The wholesale cost is about 0.01 USD per dose as of 2014.<ref>{{cite web|title=Amodiaquine|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=AMO200T&s_year=2014&year=2014&str=150-200%20mg&desc=Amodiaquine&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E5%2E3%2E1&supplement=&class_name=%2806%2E5%2E3%2E1%29Antimalarial%20medicines%2C%20for%20curative%20treatment%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=4 December 2015}}</ref> While not available in the United States,<ref>{{cite web|title=Amodiaquine|url=https://livertox.nih.gov/Amodiaquine.htm|website=Livertox|accessdate=27 November 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161127154244/https://livertox.nih.gov/Amodiaquine.htm|archivedate=27 November 2016|df=}}</ref> it is widely available in [[Africa]].<ref name=Na2012/><ref name=CDC1985>{{cite journal|last1=Centers for Disease Control|first1=(CDC).|title=Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum.|journal=MMWR. Morbidity and mortality weekly report|date=12 April 1985|volume=34|issue=14|pages=185–90, 195|pmid=3156271}}</ref>

== Medical uses ==
Amodiaquine has become an important drug in the [[combination therapy]] for malaria treatment in Africa.<ref>{{cite journal|last=Kerb|first=Reinhold|last2=Fux |last3=Morike |last4=Kremsner |last5=Gil |last6=Gleiter|last7=Schwab|title=Pharmacogenetics of antimalarial drugs: effect on metabolism and transport|journal=Lancet Infectious Diseases|year=2009|volume=9|pages=760–774|doi=10.1016/S1473-3099(09)70320-2|issue=12}}</ref> It is often used in combination with [[artesunate/amodiaquine|artensunate]] as a by mouth [[artemisinin-based combination therapy]] (ACT) for uncomplicated ''[[Plasmodium falciparum|P. falciparum]]'' malaria.<ref name=":02">{{Cite book|title=Guidelines for the Treatment of Malaria - 2nd Edition|last=|first=|publisher=World Health Organization|year=2010|isbn=9789241547925|location=|pages=33|via=}}</ref> Amodiaquine has also been found to work against chloroquine-resistant ''P. falciparum'' strains of malaria.<ref>{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/amodiaquine#section=Top|title=amodiaquine {{!}} C20H22ClN3O - PubChem|last=Pubchem|website=pubchem.ncbi.nlm.nih.gov|access-date=2016-10-28|deadurl=no|archiveurl=https://web.archive.org/web/20161029043608/https://pubchem.ncbi.nlm.nih.gov/compound/amodiaquine#section=Top|archivedate=2016-10-29|df=}}</ref>

== Interactions ==
There have been reports of increased liver toxicity in people with [[HIV/AIDS]] on [[zidovudine]] or [[efavirenz]] when treated with amodiaquine-containing ACT regimens, therefore it is recommended that these people avoid amodiaquine.<ref name=":02"/>

== Pharmacogenetics == 
It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the [[cytochrome p450]] enzyme [[CYP2C8]]. Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the [[wild-type]] allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of "poor metabolizer" phenotypes. People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity.<ref>{{cite journal|last=Elyazar|first=Iqbal|author2=Hay, Baird|title=Malaria Distribution, Prevalence, Drug Resistance, and control in Indonesia|journal=Advanced Parasitology|date=April 2011|issue=74|pages=41–175|doi=10.1016/B978-0-12-385897-9.00002-1|series=Advances in Parasitology|isbn=9780123858979|volume=74}}</ref> Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population.<ref>{{cite journal|last=Roederer|first=Mary|author2=Mcleod, Juliano|title=Can pharmacogenetics improve malaria|journal=Bulletin of World Health Organization|year=2011|volume=89|pages=838–845|doi=10.2471/BLT.11.087320|issue=11}}</ref> About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine. This information is useful in developing programs of [[pharmacovigilance]] in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.

==References==
{{Reflist}}

{{Antimalarials}}
{{Monoamine metabolism modulators}}

[[Category:Antimalarial agents]]
[[Category:Quinolines]]
[[Category:Phenols]]
[[Category:Chloroarenes]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]